The Coler Lab at Seattle Children’s Research Institute is using their expertise to support the clinical trial of an experimental coronavirus vaccine funded by National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health. The trial is being conducted at the Kaiser Permanente Washington Health Research Institute in Seattle, part of NIAID’s Infectious Diseases Clinical Research Consortium.
Study Shows Link Between COVID-19 and Heart Issues, Poor Outcomes for Patients on Ventilators (UW School of Public Health - Study led by Matt Arentz)
A University of Washington study provides some of the first details of 21 critically ill patients with the coronavirus disease 2019 (COVID-19) in the United States, most of whom were linked to exposures at a nursing home at the center of the country’s COVID-19 outbreak early on in the global crisis.
The benefits of hydroxychloroquine being investigated in multi-site clinical trial launching in April
Researchers are investigating whether hydroxychloroquine – a commonly used anti-malarial and autoimmune drug – can prevent COVID-19.
A multi-site clinical trial, led by the University of Washington Department of Global Health/International Clinical Research Center (ICRC) in collaboration with NYU Grossman School of Medicine, aims to definitively determine whether hydroxychloroquine can prevent transmission in people exposed to the virus.
In a forecast based on new data analyses, researchers find demand for ventilators and beds in US hospital intensive care units (ICUs) will far exceed capacity for COVID-19 patients as early as the second week of April. Deaths related to the current wave of COVID-19 in the US are likely to persist into July, even assuming people protect themselves and their communities by strongly adhering to social distancing measures and by taking other precautions advised by public health officials.
UW Obstetrician to Study COVID-19 Impacts on Pregnancy (UW Medicine - Quotes Kristina Adams Waldorf)
While pregnant women are included in those thought to be at high risk for COVID-19, not much is actually known yet about the virus' potential impacts on pregnancy.
But a University of Washington obstetrician and professor hopes to change that, shifting her lab's research into the new virus.
Seattle Team Gets Funding to Start Human Trials of Potentially Groundbreaking Coronavirus Treatment (Seattle Times - Quotes Corey Casper)
Seattle’s Infectious Disease Research Institute has received seven-figure funding to begin human trials on a potentially groundbreaking novel coronavirus treatment.
The study could launch within weeks, take about 11 months to complete, and enroll about 100 patients diagnosed with a COVID-19 infection that’s causing moderate to severe pneumonia. It would deploy cancer-fighting NK-cells as an immunotherapy treatment for the coronavirus rather than the current approach of antiviral medication.
Patricia García, Peru's former Minister of Health and an Affiliate Professor of Global Health at the University of Washington, spoke to Publimetro in her home country of Peru about the country's response to the coronavirus pandemic. García received a Masters of Public Health at UW and is also a professor at the School of Public Health at Cayetano Heredia University in Lima, Peru. Her areas of expertise include epidemiology, infectious diseases, and implementation science.
The following interview has been translated from Spanish.
In parts of Africa, where the HIV rate is 36 percent, researchers tested out a simple idea: They made access to care easier for people living with a chronic condition.
In a nearly three-year study in South Africa and Uganda, researchers used mobile vans in five communities to dispense care and treatment to 1,315 people living with HIV and not on antiretroviral treatment.
The randomized controlled trial, conducted between May 2016 and March 2019, found that viral suppression was 74 percent, compared to 63 percent for those seen in a clinic.